Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study
The Journal of Heart and Lung Transplantation, 06/01/2012Potena L et al.
Cyclosporine nephrotoxicity improved after a prolonged dose reduction in patients receiving MMF. The everolimus–based strategy provided a similar benefit only to patients without baseline proteinuria. While raising caution against the universal use of everolimus for kidney protection, the long–term results support the need for customized approaches in the management of drug toxicities in maintenance HT recipients.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.